There are several FDA-approved tests that are routinely used clinically, which comprise different antibody clones as the principal tools for detecting the PD-L1 biomarker, for example the Dako PD-L1 22C3 clone is specifically used for directing treatment with the anti-PD-1 agent pembrolizumab or the Ventana PD-L1 SP142 clone for the prescription of atezolizumab, both in NSCLC as well as other tumour types. This evidence concerns the gene CD274 and non-small cell lung carcinoma.